inositol has been researched along with Obesity in 66 studies
Inositol: An isomer of glucose that has traditionally been considered to be a B vitamin although it has an uncertain status as a vitamin and a deficiency syndrome has not been identified in man. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1379) Inositol phospholipids are important in signal transduction.
inositol : Any cyclohexane-1,2,3,4,5,6-hexol.
1D-chiro-inositol : Belonging to the inositol family of compounds, D-chiro-inositol (DCI) is an isomer of glucose. It is an important secondary messenger in insulin signal transduction.
muco-inositol : An inositol that is cyclohexane-1,2,3,4,5,6-hexol having a (1R,2R,3r,4R,5S,6r)-configuration.
Obesity: A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).
| Excerpt | Relevance | Reference |
|---|---|---|
| "To determine whether a combined myo-inositol, probiotics and micronutrient nutritional supplement impacts time-to-natural-conception and clinical pregnancy rates." | 9.69 | Time-to-conception and clinical pregnancy rate with a myo-inositol, probiotics, and micronutrient supplement: secondary outcomes of the NiPPeR randomized trial. ( Baker, PN; Barton, SJ; Chan, SY; Chang, HF; Chong, YS; Cutfield, WS; Ebreo, M; El-Heis, S; Godfrey, KM; Kenealy, T; Loy, SL; Nield, H; Ong, J; Tan, KM; Titcombe, P; Wong, JT, 2023) |
| "To compare the effects of insulin sensitizers metformin (MET) and myo-inositol (MI) on adiponectin levels and metabolic characteristics in women with polycystic ovary syndrome (PCOS) with respect to their body mass index (BMI)." | 9.51 | The effect of metformin and myoinositol on metabolic outcomes in women with polycystic ovary syndrome: role of body mass and adiponectin in a randomized controlled trial. ( Bjekić-Macut, J; Livadas, S; Macut, D; Malešević, G; Mastorakos, G; Micić, D; Ognjanović, S; Popović-Pejičić, S; Prtina, A; Soldat-Stanković, V; Stanković, S, 2022) |
| "Current evidence is uncertain on the potential benefit of myo-inositol supplementation in overweight and obese pregnant women." | 9.41 | The Efficacy and Safety of Myo-inositol Supplementation for the Prevention of Gestational Diabetes Mellitus in Overweight and Obese Pregnant Women: A Systematic Review and Meta-Analysis. ( Corpuz, H; Factor, PA, 2023) |
| "The aim of this study was to evaluate the effects of diet alone, and in association with metformin in monotherapy or in cotreatment with myoinositol (MYO) on menstrual irregularities, hirsutism, body weight and composition in overweight/obese women with polycystic ovary syndrome (PCOS)." | 9.16 | [Diet, metformin and inositol in overweight and obese women with polycystic ovary syndrome: effects on body composition]. ( Alibrandi, A; Giarrusso, R; Le Donne, M; Lo Monaco, I; Muraca, U, 2012) |
| "Obese women with polycystic ovary syndrome (PCOS) manifest impaired insulin-stimulated release of a d-chiro-inositol-containing inositolphosphoglycan (DCI-IPG) insulin mediator during oral glucose tolerance testing (OGTT), which appears to be restored by the administration of metformin." | 9.14 | Uncoupling between insulin and release of a D-chiro-inositol-containing inositolphosphoglycan mediator of insulin action in obese women With polycystic ovary syndrome. ( Apridonidze, T; Baillargeon, JP; Iuorno, MJ; Nestler, JE, 2010) |
| "Forty-three polycystic ovary syndrome (PCOS) overweight/obese patients were randomly treated for 6 months with: only diet (Group 1, n = 21); diet and myo-inositol (MI) 4 g + folic acid 400 µg daily (group 2, n = 10); diet in association with MI 1." | 7.91 | Effects of three treatment modalities (diet, myoinositol or myoinositol associated with D-chiro-inositol) on clinical and body composition outcomes in women with polycystic ovary syndrome. ( Alibrandi, A; Benvenga, S; Le Donne, M; Metro, D; Papa, M, 2019) |
| "Combined inositol treatment during pregnancy improves blood pressure, glucose levels at the glucose tolerance test, and leptin levels in pregnant dams with metabolic-like syndrome phenotype but not in obese pregnant dams." | 7.83 | The effect of combined inositol supplementation on maternal metabolic profile in pregnancies complicated by metabolic syndrome and obesity. ( Blackwell, SC; Facchinetti, F; Ferrari, F; Longo, M; Ontiveros, AE; Refuerzo, JS; Roberts, RP; Saade, MM; Sibai, BM, 2016) |
| "The activities of pathways for the biosynthesis of hippurate, urea and pyrimidines in hepatocytes isolated from lean livers were compared with those from three sources of fatty liver: a) the genetically obese Zucker rat, b) Sprague-Dawley rats fed a diet deficient in choline and inositol, and c) Sprague-Dawley rats fed a diet supplemented with orotic acid." | 7.67 | Biosynthesis of hippurate, urea and pyrimidines in the fatty liver: studies with rats fed orotic acid or a diet deficient in choline and inositol, and with genetically obese (Zucker) rats. ( Maswoswe, SM; Tremblay, GC, 1989) |
| "Metformin treatment was also associated with a significant decrease in LH and oestradiol levels, androgens and anti-müllerian hormone levels." | 6.84 | Metformin vs myoinositol: which is better in obese polycystic ovary syndrome patients? A randomized controlled crossover study. ( De Cicco, S; Di Florio, C; Guido, M; Immediata, V; Lanzone, A; Romualdi, D; Tagliaferri, V, 2017) |
| " On such basis, we investigated the efficacy on insulin sensitivity and hormonal parameters of 8 weeks treatment with myo-inositol (MYO) (Inofert, ItalPharmaco, Milano, Italy) at the dosage of 2 g day in a group (n = 42) of obese PCOS patients,." | 6.77 | Differential insulin response to myo-inositol administration in obese polycystic ovary syndrome patients. ( Artini, PG; Campedelli, A; Chierchia, E; Genazzani, AD; Prati, A; Rattighieri, E; Ricchieri, F; Santagni, S; Simoncini, T, 2012) |
| "To determine whether a combined myo-inositol, probiotics and micronutrient nutritional supplement impacts time-to-natural-conception and clinical pregnancy rates." | 5.69 | Time-to-conception and clinical pregnancy rate with a myo-inositol, probiotics, and micronutrient supplement: secondary outcomes of the NiPPeR randomized trial. ( Baker, PN; Barton, SJ; Chan, SY; Chang, HF; Chong, YS; Cutfield, WS; Ebreo, M; El-Heis, S; Godfrey, KM; Kenealy, T; Loy, SL; Nield, H; Ong, J; Tan, KM; Titcombe, P; Wong, JT, 2023) |
| "Obesity is an independent risk factor to develop cardiac functional and structural impairments." | 5.56 | Myo-inositol and d-chiro-inositol oral supplementation ameliorate cardiac dysfunction and remodeling in a mouse model of diet-induced obesity. ( Di Lascio, N; Faita, F; Forini, F; Kusmic, C; L'Abbate, S; Marchetti, S; Nicolini, G, 2020) |
| "To compare the effects of insulin sensitizers metformin (MET) and myo-inositol (MI) on adiponectin levels and metabolic characteristics in women with polycystic ovary syndrome (PCOS) with respect to their body mass index (BMI)." | 5.51 | The effect of metformin and myoinositol on metabolic outcomes in women with polycystic ovary syndrome: role of body mass and adiponectin in a randomized controlled trial. ( Bjekić-Macut, J; Livadas, S; Macut, D; Malešević, G; Mastorakos, G; Micić, D; Ognjanović, S; Popović-Pejičić, S; Prtina, A; Soldat-Stanković, V; Stanković, S, 2022) |
| "Polycystic ovary syndrome is characterized by several endocrine impairments, insulin resistance and hyperinsulinemia." | 5.51 | Differential insulin response to oral glucose tolerance test (OGTT) in overweight/obese polycystic ovary syndrome patients undergoing to myo-inositol (MYO), alpha lipoic acid (ALA), or combination of both. ( Genazzani, AD; Marchini, F; Napolitano, A; Petrillo, T; Prati, A; Simoncini, T, 2019) |
| "Current evidence is uncertain on the potential benefit of myo-inositol supplementation in overweight and obese pregnant women." | 5.41 | The Efficacy and Safety of Myo-inositol Supplementation for the Prevention of Gestational Diabetes Mellitus in Overweight and Obese Pregnant Women: A Systematic Review and Meta-Analysis. ( Corpuz, H; Factor, PA, 2023) |
| "In an open-label, randomized trial, myo-inositol (2 g plus 200 micrograms folic acid twice a day) or placebo (200 micrograms folic acid twice a day) was administered from the first trimester to delivery in pregnant obese women (prepregnancy body mass index 30 or greater." | 5.20 | Myo-inositol Supplementation for Prevention of Gestational Diabetes in Obese Pregnant Women: A Randomized Controlled Trial. ( Corrado, F; D'Anna, R; Di Benedetto, A; Facchinetti, F; Interdonato, ML; Neri, I; Petrella, E; Pintaudi, B; Santamaria, A; Scilipoti, A, 2015) |
| " Since it has been demonstrated a high incidence of insulin resistance in PCOS patients, our study aimed to evaluate the efficacy of the integrative treatment with D-chiro-inositol (DCI) (500 mg die, per os, for 12 weeks) on hormonal parameters and insulin sensitivity in a group of overweight/obese PCOS patients (body mass index; BMI > 26)." | 5.19 | Modulatory role of D-chiro-inositol (DCI) on LH and insulin secretion in obese PCOS patients. ( Chierchia, E; Despini, G; Genazzani, AD; Marini, G; Prati, A; Rattighieri, E; Santagni, S; Simoncini, T, 2014) |
| "The aim of this study was to evaluate the effects of diet alone, and in association with metformin in monotherapy or in cotreatment with myoinositol (MYO) on menstrual irregularities, hirsutism, body weight and composition in overweight/obese women with polycystic ovary syndrome (PCOS)." | 5.16 | [Diet, metformin and inositol in overweight and obese women with polycystic ovary syndrome: effects on body composition]. ( Alibrandi, A; Giarrusso, R; Le Donne, M; Lo Monaco, I; Muraca, U, 2012) |
| "The combined administration of MI and DCI in physiological plasma ratio (40:1) should be considered as the first line approach in PCOS overweight patients, being able to reduce the metabolic and clinical alteration of PCOS and, therefore, reduce the risk of metabolic syndrome." | 5.16 | The combined therapy with myo-inositol and D-chiro-inositol reduces the risk of metabolic disease in PCOS overweight patients compared to myo-inositol supplementation alone. ( Nordio, M; Proietti, E, 2012) |
| "Obese women with polycystic ovary syndrome (PCOS) manifest impaired insulin-stimulated release of a d-chiro-inositol-containing inositolphosphoglycan (DCI-IPG) insulin mediator during oral glucose tolerance testing (OGTT), which appears to be restored by the administration of metformin." | 5.14 | Uncoupling between insulin and release of a D-chiro-inositol-containing inositolphosphoglycan mediator of insulin action in obese women With polycystic ovary syndrome. ( Apridonidze, T; Baillargeon, JP; Iuorno, MJ; Nestler, JE, 2010) |
| " We conclude that plasma levels of both pinitol and D-chiro-inositol are very responsive to pinitol ingestion, but insulin sensitivity does not increase after pinitol treatment in individuals with obesity and mild type 2 diabetes." | 5.09 | Effect of pinitol treatment on insulin action in subjects with insulin resistance. ( Christiansen, M; Davis, A; Hellerstein, MK; Horowitz, JF; Klein, S; Ostlund, RE, 2000) |
| "Myo-inositol supplementation at physiological doses during lactation improves metabolic health and prevents the programmed trend to develop insulin resistance and hypertriglyceridemia in male rats acquired by inadequate fetal nutrition and exacerbated by a diabetogenic diet in adulthood." | 4.02 | Sex-Specific Effects of Myo-Inositol Ingested During Lactation in the Improvement of Metabolic Health in Adult Rats. ( Castillo, P; Núñez, P; Otero, D; Palou, A; Palou, M; Picó, C, 2021) |
| "Forty-three polycystic ovary syndrome (PCOS) overweight/obese patients were randomly treated for 6 months with: only diet (Group 1, n = 21); diet and myo-inositol (MI) 4 g + folic acid 400 µg daily (group 2, n = 10); diet in association with MI 1." | 3.91 | Effects of three treatment modalities (diet, myoinositol or myoinositol associated with D-chiro-inositol) on clinical and body composition outcomes in women with polycystic ovary syndrome. ( Alibrandi, A; Benvenga, S; Le Donne, M; Metro, D; Papa, M, 2019) |
| "A secondary analysis of databases from 3 randomized, controlled trials (595 women enrolled) in which women who were at risk for gestational diabetes mellitus (a parent with type 2 diabetes mellitus, obese, or overweight) were supplemented with myo-inositol (4 g/d) throughout pregnancy." | 3.88 | Clinical and metabolic outcomes in pregnant women at risk for gestational diabetes mellitus supplemented with myo-inositol: a secondary analysis from 3 RCTs. ( Alibrandi, A; Corrado, F; D'Anna, R; Di Benedetto, A; Facchinetti, F; Pintaudi, B; Santamaria, A, 2018) |
| "Combined inositol treatment during pregnancy improves blood pressure, glucose levels at the glucose tolerance test, and leptin levels in pregnant dams with metabolic-like syndrome phenotype but not in obese pregnant dams." | 3.83 | The effect of combined inositol supplementation on maternal metabolic profile in pregnancies complicated by metabolic syndrome and obesity. ( Blackwell, SC; Facchinetti, F; Ferrari, F; Longo, M; Ontiveros, AE; Refuerzo, JS; Roberts, RP; Saade, MM; Sibai, BM, 2016) |
| "We previously reported that a chronic supplementation with myo-inositol (MI) improved insulin sensitivity and reduced fat accretion in mice." | 3.81 | Abnormalities in myo-inositol metabolism associated with type 2 diabetes in mice fed a high-fat diet: benefits of a dietary myo-inositol supplementation. ( Croze, ML; Géloën, A; Soulage, CO, 2015) |
| "Higher triglyceride and lower HDL levels statistically account for the association between BMI and myo-inositol, pointing toward a potentially critical role for dyslipidemia in the development of cerebral neurochemical alterations in obesity." | 3.79 | Dyslipidemia links obesity to early cerebral neurochemical alterations. ( Gonzales, MM; Haley, AP; Tanaka, H; Tarumi, T, 2013) |
| "The activities of pathways for the biosynthesis of hippurate, urea and pyrimidines in hepatocytes isolated from lean livers were compared with those from three sources of fatty liver: a) the genetically obese Zucker rat, b) Sprague-Dawley rats fed a diet deficient in choline and inositol, and c) Sprague-Dawley rats fed a diet supplemented with orotic acid." | 3.67 | Biosynthesis of hippurate, urea and pyrimidines in the fatty liver: studies with rats fed orotic acid or a diet deficient in choline and inositol, and with genetically obese (Zucker) rats. ( Maswoswe, SM; Tremblay, GC, 1989) |
| "Metformin treatment was also associated with a significant decrease in LH and oestradiol levels, androgens and anti-müllerian hormone levels." | 2.84 | Metformin vs myoinositol: which is better in obese polycystic ovary syndrome patients? A randomized controlled crossover study. ( De Cicco, S; Di Florio, C; Guido, M; Immediata, V; Lanzone, A; Romualdi, D; Tagliaferri, V, 2017) |
| " On such basis, we investigated the efficacy on insulin sensitivity and hormonal parameters of 8 weeks treatment with myo-inositol (MYO) (Inofert, ItalPharmaco, Milano, Italy) at the dosage of 2 g day in a group (n = 42) of obese PCOS patients,." | 2.77 | Differential insulin response to myo-inositol administration in obese polycystic ovary syndrome patients. ( Artini, PG; Campedelli, A; Chierchia, E; Genazzani, AD; Prati, A; Rattighieri, E; Ricchieri, F; Santagni, S; Simoncini, T, 2012) |
| "Postprandial hyperglycemia and hyperlipidemia are considered risk factors for cardiovascular disease." | 2.72 | An alpha-glucosidase inhibitor, voglibose, reduces oxidative stress markers and soluble intercellular adhesion molecule 1 in obese type 2 diabetic patients. ( Aizawa-Abe, M; Kuzuya, H; Ogawa, Y; Satoh, N; Shimatsu, A; Suganami, T; Yamada, K, 2006) |
| "The rise in gestational diabetes (GDM), defined as first onset or diagnosis of diabetes in pregnancy, is a global problem." | 2.52 | Nutritional manipulation for the primary prevention of gestational diabetes mellitus: a meta-analysis of randomised studies. ( Chamillard, M; Hitman, GA; Khan, KS; Rogozińska, E; Thangaratinam, S, 2015) |
| "Postprandial hyperglycemia is frequently associated with visceral obesity which plays a key role in metabolic abnormalities such as dyslipidemia and hypertension." | 2.42 | [Pharmacological treatment of postprandial hyperglycemia in hypertensive patients with type 2 diabetes mellitus]. ( Yamada, K, 2003) |
| "Obesity is associated with adverse effects on brain health, including an increased risk of neurodegenerative diseases." | 1.91 | Change in medial frontal cerebral metabolite concentrations following bariatric surgery. ( Bottari, SA; Britton, MK; Chen, A; Cohen, RA; Friedman, J; Gunstad, J; Porges, EC; Williamson, JB; Woods, AJ, 2023) |
| "Inositol depletion has been associated with diabetes and related complications." | 1.91 | Inositol in Disease and Development: Roles of Catabolism via ( Contreras, A; Eldon, ED; Jones, MK; Klig, LS, 2023) |
| "Myo-inositol (MYO) is an insulin-sensitizing compound used in PCOS patients; however, its insulin-sensitizing mechanism is unclear." | 1.56 | The insulin-sensitizing mechanism of myo-inositol is associated with AMPK activation and GLUT-4 expression in human endometrial cells exposed to a PCOS environment. ( Cabrera-Cruz, H; Oróstica, L; Plaza-Parrochia, F; Romero, C; Torres-Pinto, I; Vega, M, 2020) |
| "Obesity is an independent risk factor to develop cardiac functional and structural impairments." | 1.56 | Myo-inositol and d-chiro-inositol oral supplementation ameliorate cardiac dysfunction and remodeling in a mouse model of diet-induced obesity. ( Di Lascio, N; Faita, F; Forini, F; Kusmic, C; L'Abbate, S; Marchetti, S; Nicolini, G, 2020) |
| "Obesity is becoming pandemic and is associated with impaired reproductive potential." | 1.56 | Effects of α-lipoic acid and myo-inositol supplementation on the oocyte environment of infertile obese women: A preliminary study. ( Anelli, GM; Cetin, I; Lisso, F; Mandò, C; Marzorati, A; Novielli, C; Oneta, M; Parrilla, B; Savasi, VM, 2020) |
| "Polycystic ovary syndrome is characterized by several endocrine impairments, insulin resistance and hyperinsulinemia." | 1.51 | Differential insulin response to oral glucose tolerance test (OGTT) in overweight/obese polycystic ovary syndrome patients undergoing to myo-inositol (MYO), alpha lipoic acid (ALA), or combination of both. ( Genazzani, AD; Marchini, F; Napolitano, A; Petrillo, T; Prati, A; Simoncini, T, 2019) |
| "Severe hypertriglyceridemia was considered to have been a consequence of impaired insulin action and his apolipoprotein E4/2 phenotype." | 1.51 | Eruptive xanthomas in a patient with soft-drink diabetic ketosis and apolipoprotein E4/2. ( Aiba, S; Imai, J; Katagiri, H; Kikuchi, K; Kohata, M; Kurosawa, S; Nakajima, T; Satake, C; Sawada, S; Takahashi, K; Takeda, K; Tsuchiya, S, 2019) |
| " Increasing the bioavailability of arginine, the precursor of nitric oxide, thus potentially offers protection against end-stage disease." | 1.34 | Metabolic effects of a novel silicate inositol complex of the nitric oxide precursor arginine in the obese insulin-resistant JCR:LA-cp rat. ( Kelly, SE; Proctor, SD; Russell, JC; Vine, DF, 2007) |
| " Chronic administration of D-pinitol (100 mg kg(-1) i." | 1.31 | Insulin-like effect of pinitol. ( Bailey, CJ; Bates, SH; Jones, RB, 2000) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (3.03) | 18.7374 |
| 1990's | 6 (9.09) | 18.2507 |
| 2000's | 9 (13.64) | 29.6817 |
| 2010's | 30 (45.45) | 24.3611 |
| 2020's | 19 (28.79) | 2.80 |
| Authors | Studies |
|---|---|
| Soldat-Stanković, V | 1 |
| Popović-Pejičić, S | 1 |
| Stanković, S | 1 |
| Prtina, A | 1 |
| Malešević, G | 1 |
| Bjekić-Macut, J | 1 |
| Livadas, S | 1 |
| Ognjanović, S | 1 |
| Mastorakos, G | 1 |
| Micić, D | 1 |
| Macut, D | 1 |
| Yang, Q | 1 |
| Zhang, Y | 1 |
| Li, L | 1 |
| Li, J | 1 |
| Li, Y | 1 |
| Han, L | 1 |
| Wang, M | 1 |
| Chen, Y | 1 |
| Wu, Z | 1 |
| Huang, S | 1 |
| Wang, X | 1 |
| He, S | 2 |
| Liu, L | 1 |
| Hu, Y | 1 |
| Chen, L | 1 |
| Chen, P | 1 |
| Liu, S | 1 |
| Shan, B | 1 |
| Zheng, L | 1 |
| Duan, SZ | 1 |
| Song, Z | 1 |
| Jiang, L | 1 |
| Wang, QA | 1 |
| Gan, Z | 1 |
| Song, BL | 1 |
| Liu, J | 1 |
| Rui, L | 1 |
| Shao, M | 1 |
| Liu, Y | 1 |
| Hassan, S | 1 |
| Shah, M | 1 |
| Malik, MO | 1 |
| Ehtesham, E | 1 |
| Habib, SH | 1 |
| Rauf, B | 1 |
| Bottari, SA | 1 |
| Cohen, RA | 1 |
| Friedman, J | 1 |
| Porges, EC | 1 |
| Chen, A | 1 |
| Britton, MK | 1 |
| Gunstad, J | 1 |
| Woods, AJ | 1 |
| Williamson, JB | 1 |
| Chan, SY | 1 |
| Barton, SJ | 1 |
| Loy, SL | 1 |
| Chang, HF | 1 |
| Titcombe, P | 1 |
| Wong, JT | 1 |
| Ebreo, M | 1 |
| Ong, J | 1 |
| Tan, KM | 1 |
| Nield, H | 1 |
| El-Heis, S | 1 |
| Kenealy, T | 1 |
| Chong, YS | 1 |
| Baker, PN | 1 |
| Cutfield, WS | 1 |
| Godfrey, KM | 1 |
| Contreras, A | 1 |
| Jones, MK | 1 |
| Eldon, ED | 1 |
| Klig, LS | 1 |
| Monastra, G | 1 |
| Gambioli, R | 1 |
| Unfer, V | 1 |
| Forte, G | 1 |
| Maymo-Masip, E | 1 |
| Comitato, R | 1 |
| Mukherjee, S | 1 |
| Chakraborty, M | 1 |
| Haubner, J | 1 |
| Ernst, G | 1 |
| DePasquale, M | 1 |
| Carpenter, D | 1 |
| Barrow, JC | 1 |
| Chakraborty, A | 2 |
| Factor, PA | 1 |
| Corpuz, H | 1 |
| Cabrera-Cruz, H | 1 |
| Oróstica, L | 1 |
| Plaza-Parrochia, F | 1 |
| Torres-Pinto, I | 1 |
| Romero, C | 1 |
| Vega, M | 1 |
| Artini, PG | 2 |
| Obino, MER | 1 |
| Micelli, E | 1 |
| Malacarne, E | 1 |
| Vacca, C | 1 |
| Papini, F | 1 |
| Cela, V | 1 |
| Kato, J | 1 |
| Shirakami, Y | 1 |
| Mizutani, T | 1 |
| Kubota, M | 1 |
| Sakai, H | 1 |
| Ibuka, T | 1 |
| Shimizu, M | 1 |
| L'Abbate, S | 1 |
| Nicolini, G | 1 |
| Forini, F | 1 |
| Marchetti, S | 1 |
| Di Lascio, N | 1 |
| Faita, F | 1 |
| Kusmic, C | 1 |
| De Diego, MV | 1 |
| Gómez-Pardo, O | 1 |
| Groar, JK | 1 |
| López-Escobar, A | 1 |
| Martín-Estal, I | 1 |
| Castilla-Cortázar, I | 1 |
| Rodríguez-Zambrano, MÁ | 1 |
| Palladino, E | 1 |
| Van Mieghem, T | 1 |
| Connor, KL | 1 |
| Novielli, C | 1 |
| Anelli, GM | 1 |
| Lisso, F | 1 |
| Marzorati, A | 1 |
| Parrilla, B | 1 |
| Oneta, M | 1 |
| Savasi, VM | 1 |
| Cetin, I | 1 |
| Mandò, C | 1 |
| Castillo, P | 1 |
| Palou, M | 1 |
| Otero, D | 1 |
| Núñez, P | 1 |
| Palou, A | 1 |
| Picó, C | 1 |
| Bond, DJ | 1 |
| Silveira, LE | 1 |
| MacMillan, EL | 1 |
| Torres, IJ | 1 |
| Lang, DJ | 1 |
| Su, W | 1 |
| Honer, WG | 1 |
| Lam, RW | 1 |
| Yatham, LN | 1 |
| López-Domènech, S | 1 |
| Bañuls, C | 1 |
| de Marañón, AM | 1 |
| Abab-Jiménez, Z | 1 |
| Morillas, C | 1 |
| Gómez-Abril, SÁ | 1 |
| Rovira-Llopis, S | 1 |
| Víctor, VM | 1 |
| Hernández-Mijares, A | 1 |
| Rocha, M | 1 |
| Santamaria, A | 2 |
| Alibrandi, A | 3 |
| Di Benedetto, A | 2 |
| Pintaudi, B | 2 |
| Corrado, F | 2 |
| Facchinetti, F | 3 |
| D'Anna, R | 2 |
| Baader-Pagler, T | 1 |
| Eckhardt, M | 1 |
| Himmelsbach, F | 1 |
| Sauer, A | 1 |
| Stierstorfer, BE | 1 |
| Hamilton, BS | 1 |
| Ortiz-Flores, AE | 1 |
| Luque-Ramírez, M | 1 |
| Escobar-Morreale, HF | 1 |
| Tsuchiya, S | 1 |
| Sawada, S | 1 |
| Takeda, K | 1 |
| Takahashi, K | 1 |
| Nakajima, T | 1 |
| Kohata, M | 1 |
| Kurosawa, S | 1 |
| Satake, C | 1 |
| Imai, J | 1 |
| Kikuchi, K | 1 |
| Aiba, S | 1 |
| Katagiri, H | 2 |
| Le Donne, M | 2 |
| Metro, D | 1 |
| Papa, M | 1 |
| Benvenga, S | 1 |
| Genazzani, AD | 4 |
| Prati, A | 3 |
| Marchini, F | 1 |
| Petrillo, T | 1 |
| Napolitano, A | 1 |
| Simoncini, T | 3 |
| Advani, K | 1 |
| Batra, M | 1 |
| Tajpuriya, S | 1 |
| Gupta, R | 1 |
| Saraswat, A | 1 |
| Nagar, HD | 1 |
| Makwana, L | 1 |
| Kshirsagar, S | 1 |
| Kaul, P | 1 |
| Ghosh, AK | 1 |
| Pradhan, S | 1 |
| Mehta, A | 1 |
| Jaiswal, A | 1 |
| Nakhate, KT | 1 |
| Kamdi, S | 1 |
| de Castro, NM | 1 |
| Yaqoob, P | 1 |
| de la Fuente, M | 1 |
| Baeza, I | 1 |
| Claus, SP | 1 |
| Minozzi, M | 1 |
| Nordio, M | 2 |
| Pajalich, R | 1 |
| Haley, AP | 2 |
| Gonzales, MM | 2 |
| Tarumi, T | 2 |
| Tanaka, H | 2 |
| Cappelli, V | 1 |
| Di Sabatino, A | 1 |
| Musacchio, MC | 1 |
| De Leo, V | 1 |
| Santagni, S | 2 |
| Rattighieri, E | 2 |
| Chierchia, E | 2 |
| Despini, G | 1 |
| Marini, G | 1 |
| Suzuki, S | 1 |
| Suzuki, C | 1 |
| Hinokio, Y | 1 |
| Ishigaki, Y | 1 |
| Kanzaki, M | 1 |
| Azev, VN | 1 |
| Chakraborty, N | 1 |
| d'Alarcao, M | 1 |
| Rogozińska, E | 1 |
| Chamillard, M | 1 |
| Hitman, GA | 1 |
| Khan, KS | 1 |
| Thangaratinam, S | 1 |
| Croze, ML | 1 |
| Géloën, A | 1 |
| Soulage, CO | 1 |
| Scilipoti, A | 1 |
| Interdonato, ML | 1 |
| Petrella, E | 1 |
| Neri, I | 1 |
| Chang, HH | 1 |
| Chao, HN | 1 |
| Walker, CS | 1 |
| Choong, SY | 1 |
| Phillips, A | 1 |
| Loomes, KM | 1 |
| Ferrari, F | 1 |
| Ontiveros, AE | 1 |
| Roberts, RP | 1 |
| Saade, MM | 1 |
| Blackwell, SC | 1 |
| Sibai, BM | 1 |
| Refuerzo, JS | 1 |
| Longo, M | 1 |
| Legro, RS | 1 |
| Tagliaferri, V | 1 |
| Romualdi, D | 1 |
| Immediata, V | 1 |
| De Cicco, S | 1 |
| Di Florio, C | 1 |
| Lanzone, A | 1 |
| Guido, M | 1 |
| Moritoh, Y | 1 |
| Takeuchi, K | 1 |
| Hazama, M | 1 |
| Baillargeon, JP | 1 |
| Iuorno, MJ | 1 |
| Apridonidze, T | 1 |
| Nestler, JE | 1 |
| Koldobskiy, MA | 1 |
| Bello, NT | 1 |
| Maxwell, M | 1 |
| Potter, JJ | 1 |
| Juluri, KR | 1 |
| Maag, D | 1 |
| Kim, S | 1 |
| Huang, AS | 1 |
| Dailey, MJ | 1 |
| Saleh, M | 1 |
| Snowman, AM | 1 |
| Moran, TH | 1 |
| Mezey, E | 1 |
| Snyder, SH | 1 |
| Fujitaka, K | 1 |
| Otani, H | 1 |
| Jo, F | 1 |
| Jo, H | 1 |
| Nomura, E | 1 |
| Iwasaki, M | 1 |
| Nishikawa, M | 1 |
| Iwasaka, T | 1 |
| Narita, T | 1 |
| Yokoyama, H | 1 |
| Yamashita, R | 1 |
| Sato, T | 1 |
| Hosoba, M | 1 |
| Morii, T | 1 |
| Fujita, H | 1 |
| Tsukiyama, K | 1 |
| Yamada, Y | 1 |
| Giarrusso, R | 1 |
| Lo Monaco, I | 1 |
| Muraca, U | 1 |
| Ricchieri, F | 1 |
| Campedelli, A | 1 |
| Proietti, E | 1 |
| Eagan, DE | 1 |
| Vaghasia, M | 1 |
| Odaka, H | 1 |
| Yamada, K | 2 |
| Mori, Y | 1 |
| Kitahara, Y | 1 |
| Miura, K | 1 |
| Itoh, Y | 1 |
| Tajima, N | 1 |
| Satoh, N | 1 |
| Shimatsu, A | 1 |
| Aizawa-Abe, M | 1 |
| Suganami, T | 1 |
| Kuzuya, H | 1 |
| Ogawa, Y | 1 |
| Proctor, SD | 1 |
| Kelly, SE | 1 |
| Vine, DF | 1 |
| Russell, JC | 1 |
| Best, L | 1 |
| Malaisse, WJ | 1 |
| Dayhaw-Barker, P | 1 |
| Zawalich, WS | 1 |
| Zawalich, KC | 1 |
| Ortmeyer, HK | 1 |
| Davis, A | 1 |
| Christiansen, M | 1 |
| Horowitz, JF | 1 |
| Klein, S | 1 |
| Hellerstein, MK | 1 |
| Ostlund, RE | 1 |
| Bates, SH | 1 |
| Jones, RB | 1 |
| Bailey, CJ | 1 |
| Larner, J | 1 |
| McCaleb, ML | 1 |
| Sredy, J | 1 |
| Hotta, N | 1 |
| Sano, T | 1 |
| Figlewicz, D | 1 |
| Szot, P | 1 |
| Greenwood, MR | 1 |
| Maswoswe, SM | 1 |
| Tremblay, GC | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effects of Combined Resveratrol and Myo-inositol on Altered Metabolic, Endocrine Parameters and Perceived Stress in Patients With Polycystic Ovarian Syndrome[NCT04867252] | Phase 2 | 88 participants (Actual) | Interventional | 2021-05-03 | Completed | ||
| Myoinositol Supplementation, Insulin Resistance and Fetal Sonographic Parameters in Gestational Diabetes, Diet Treated: a Prospective, Randomized, Placebo-controlled Study[NCT03763669] | 120 participants (Actual) | Interventional | 2018-11-14 | Completed | |||
| The Effect Birth Outcome and Diabetes Management of Planned Behavior Theory Based Education Model in Women With Gestational Diabetes[NCT04874922] | 66 participants (Actual) | Interventional | 2021-05-15 | Completed | |||
| Myo-inositol May Prevent Gestational Diabetes in Obese Women[NCT01047982] | 220 participants (Actual) | Interventional | 2010-03-31 | Completed | |||
| Reduction of Insulin Therapy Under Myo-inositol for the Treatment of Gestational Diabetes Mellitus: a Randomized Multicenter and Prospective Trial. MYO-GDM Study[NCT03875755] | 1,080 participants (Anticipated) | Interventional | 2020-03-04 | Recruiting | |||
| Effects of a Supplementation With Zinc and Myo-inositol in Paediatric Obesity[NCT03283813] | Phase 4 | 60 participants (Anticipated) | Interventional | 2018-02-05 | Recruiting | ||
| [NCT01514942] | Phase 4 | 0 participants | Interventional | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
9 reviews available for inositol and Obesity
| Article | Year |
|---|---|
The Efficacy and Safety of Myo-inositol Supplementation for the Prevention of Gestational Diabetes Mellitus in Overweight and Obese Pregnant Women: A Systematic Review and Meta-Analysis.
Topics: Diabetes, Gestational; Dietary Supplements; Female; Humans; Hypertension, Pregnancy-Induced; Infant, | 2023 |
Pharmacotherapeutic management of comorbid polycystic ovary syndrome and diabetes.
Topics: Animals; Diabetes Mellitus; Female; Glucose Intolerance; Humans; Inositol; Insulin; Insulin Resistan | 2018 |
Nutritional manipulation for the primary prevention of gestational diabetes mellitus: a meta-analysis of randomised studies.
Topics: Clinical Trials as Topic; Databases, Factual; Diabetes, Gestational; Female; Humans; Inositol; Nutri | 2015 |
Inositol as putative integrative treatment for PCOS.
Topics: Female; Humans; Hyperandrogenism; Hyperinsulinism; Inositol; Inositol Phosphates; Insulin; Insulin R | 2016 |
Ovulation induction in polycystic ovary syndrome: Current options.
Topics: Anovulation; Anti-Obesity Agents; Aromatase Inhibitors; Bariatric Surgery; Clomiphene; Diet Therapy; | 2016 |
[alpha-Glucosidase inhibitor, its structure and mechanism of antidiabetic action].
Topics: Acarbose; Animals; Diabetes Mellitus, Type 2; Enzyme Inhibitors; Glycoside Hydrolase Inhibitors; Hum | 2002 |
[Pharmacological treatment of postprandial hyperglycemia in hypertensive patients with type 2 diabetes mellitus].
Topics: Acarbose; Cyclohexanes; Diabetes Complications; Diabetes Mellitus; Diabetes Mellitus, Type 2; Enzyme | 2003 |
Phospholipids and islet function.
Topics: Amino Acids; Animals; Arachidonic Acid; Arachidonic Acids; Calcium; Fatty Acids; Glucose; Hormones; | 1983 |
Mechanisms of pathogenesis in diabetes mellitus.
Topics: Aldehyde Reductase; Animals; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Histocompatibilit | 1995 |
15 trials available for inositol and Obesity
| Article | Year |
|---|---|
The effect of metformin and myoinositol on metabolic outcomes in women with polycystic ovary syndrome: role of body mass and adiponectin in a randomized controlled trial.
Topics: Adiponectin; Adult; Blood Glucose; Body Composition; Body Mass Index; Female; Gonadal Steroid Hormon | 2022 |
Treatment with combined resveratrol and myoinositol ameliorates endocrine, metabolic alterations and perceived stress response in women with PCOS: a double-blind randomized clinical trial.
Topics: Adiponectin; Adult; Female; Follicle Stimulating Hormone; Humans; Inositol; Insulin; Luteinizing Hor | 2023 |
Time-to-conception and clinical pregnancy rate with a myo-inositol, probiotics, and micronutrient supplement: secondary outcomes of the NiPPeR randomized trial.
Topics: Dietary Supplements; Double-Blind Method; Female; Humans; Inositol; Micronutrients; Obesity; Overwei | 2023 |
[Evaluation of a new association between insulin-sensitizers and α-lipoic acid in obese women affected by PCOS].
Topics: Adult; Antioxidants; Blood Glucose; Body Mass Index; Drug Therapy, Combination; Electron Transport; | 2013 |
Modulatory role of D-chiro-inositol (DCI) on LH and insulin secretion in obese PCOS patients.
Topics: Adult; Body Mass Index; Dietary Supplements; Family Health; Female; Gonadotropin-Releasing Hormone; | 2014 |
Myo-inositol Supplementation for Prevention of Gestational Diabetes in Obese Pregnant Women: A Randomized Controlled Trial.
Topics: Adult; Blood Glucose; Body Mass Index; Comorbidity; Diabetes, Gestational; Dietary Supplements; Drug | 2015 |
Myo-inositol Supplementation for Prevention of Gestational Diabetes in Obese Pregnant Women: A Randomized Controlled Trial.
Topics: Adult; Blood Glucose; Body Mass Index; Comorbidity; Diabetes, Gestational; Dietary Supplements; Drug | 2015 |
Myo-inositol Supplementation for Prevention of Gestational Diabetes in Obese Pregnant Women: A Randomized Controlled Trial.
Topics: Adult; Blood Glucose; Body Mass Index; Comorbidity; Diabetes, Gestational; Dietary Supplements; Drug | 2015 |
Myo-inositol Supplementation for Prevention of Gestational Diabetes in Obese Pregnant Women: A Randomized Controlled Trial.
Topics: Adult; Blood Glucose; Body Mass Index; Comorbidity; Diabetes, Gestational; Dietary Supplements; Drug | 2015 |
Metformin vs myoinositol: which is better in obese polycystic ovary syndrome patients? A randomized controlled crossover study.
Topics: Adult; Cross-Over Studies; Female; Humans; Hypoglycemic Agents; Inositol; Metformin; Obesity; Outcom | 2017 |
Uncoupling between insulin and release of a D-chiro-inositol-containing inositolphosphoglycan mediator of insulin action in obese women With polycystic ovary syndrome.
Topics: Adolescent; Adult; Case-Control Studies; Cross-Sectional Studies; Diazoxide; Female; Glucose Clamp T | 2010 |
Comparison of metabolic profile and adiponectin level with pioglitazone versus voglibose in patients with type-2 diabetes mellitus associated with metabolic syndrome.
Topics: Adiponectin; Diabetes Mellitus, Type 2; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; | 2011 |
Comparisons of the effects of 12-week administration of miglitol and voglibose on the responses of plasma incretins after a mixed meal in Japanese type 2 diabetic patients.
Topics: 1-Deoxynojirimycin; Asian People; Diabetes Mellitus, Type 2; Drug Administration Schedule; Female; G | 2012 |
[Diet, metformin and inositol in overweight and obese women with polycystic ovary syndrome: effects on body composition].
Topics: Adolescent; Adult; Body Composition; Combined Modality Therapy; Drug Therapy, Combination; Female; H | 2012 |
Differential insulin response to myo-inositol administration in obese polycystic ovary syndrome patients.
Topics: Adult; Body Mass Index; Dietary Supplements; Female; Folic Acid; Follicle Stimulating Hormone; Gluco | 2012 |
The combined therapy with myo-inositol and D-chiro-inositol reduces the risk of metabolic disease in PCOS overweight patients compared to myo-inositol supplementation alone.
Topics: Adolescent; Adult; Analysis of Variance; Biomarkers; Drug Combinations; Female; Humans; Inositol; Me | 2012 |
An alpha-glucosidase inhibitor, voglibose, reduces oxidative stress markers and soluble intercellular adhesion molecule 1 in obese type 2 diabetic patients.
Topics: Adult; Biomarkers; Diabetes Mellitus, Type 2; Female; Glycoside Hydrolase Inhibitors; Humans; Hyperg | 2006 |
Effect of pinitol treatment on insulin action in subjects with insulin resistance.
Topics: Blood Glucose; Diabetes Mellitus; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucose Cl | 2000 |
42 other studies available for inositol and Obesity
| Article | Year |
|---|---|
D-
Topics: Adiponectin; AMP-Activated Protein Kinases; Animals; Body Weight; Diet, High-Fat; Fatty Liver; Gluco | 2022 |
Adipocyte IRE1α promotes PGC1α mRNA decay and restrains adaptive thermogenesis.
Topics: Adipocytes; Adrenergic Agents; Animals; Endoribonucleases; Inositol; Mice; Obesity; Peroxisome Proli | 2022 |
Change in medial frontal cerebral metabolite concentrations following bariatric surgery.
Topics: Bariatric Surgery; Choline; Creatine; Humans; Inositol; Obesity; Proton Magnetic Resonance Spectrosc | 2023 |
Inositol in Disease and Development: Roles of Catabolism via
Topics: Animals; Drosophila melanogaster; Glucose; Inositol; Inositol Oxygenase; Obesity; RNA, Messenger | 2023 |
D-Chiro-Inositol and Myo-Inositol Induce WAT/BAT Trans-Differentiation in Two Different Human Adipocyte Models (SGBS and LiSa-2).
Topics: Adipocytes; Adipose Tissue, Brown; Adipose Tissue, White; Cell Transdifferentiation; Humans; Inosito | 2023 |
The IP6K Inhibitor LI-2242 Ameliorates Diet-Induced Obesity, Hyperglycemia, and Hepatic Steatosis in Mice by Improving Cell Metabolism and Insulin Signaling.
Topics: Animals; Diet; Diphosphates; Hyperglycemia; Inositol; Insulin; Insulin Resistance; Lipid Metabolism; | 2023 |
The insulin-sensitizing mechanism of myo-inositol is associated with AMPK activation and GLUT-4 expression in human endometrial cells exposed to a PCOS environment.
Topics: Adult; AMP-Activated Protein Kinases; Cells, Cultured; Endometrium; Enzyme Activation; Female; Gluco | 2020 |
Effect of d-chiro-inositol and alpha-lipoic acid combination on COH outcomes in overweight/obese PCOS women.
Topics: Adult; Drug Therapy, Combination; Female; Fertility Agents, Female; Fertilization in Vitro; Gonadotr | 2020 |
Alpha-Glucosidase Inhibitor Voglibose Suppresses Azoxymethane-Induced Colonic Preneoplastic Lesions in Diabetic and Obese Mice.
Topics: Animals; Antioxidants; Azoxymethane; Biomarkers; Biopsy; Cell Proliferation; Colonic Neoplasms; Cyto | 2020 |
Myo-inositol and d-chiro-inositol oral supplementation ameliorate cardiac dysfunction and remodeling in a mouse model of diet-induced obesity.
Topics: Action Potentials; Administration, Oral; Animals; Arrhythmias, Cardiac; Diet, High-Fat; Dietary Supp | 2020 |
Metabolic impact of current therapeutic strategies in Polycystic Ovary Syndrome: a preliminary study.
Topics: Adolescent; Adult; Blood Glucose; Contraceptives, Oral, Combined; Female; Glycated Hemoglobin; Human | 2020 |
Diet Alters Micronutrient Pathways in the Gut and Placenta that Regulate Fetal Growth and Development in Pregnant Mice.
Topics: Animal Feed; Animal Nutritional Physiological Phenomena; Animals; Caloric Restriction; Diet; Diet, H | 2021 |
Effects of α-lipoic acid and myo-inositol supplementation on the oocyte environment of infertile obese women: A preliminary study.
Topics: Adult; Anti-Inflammatory Agents; Antioxidants; Dietary Supplements; DNA, Mitochondrial; Female; Fert | 2020 |
Sex-Specific Effects of Myo-Inositol Ingested During Lactation in the Improvement of Metabolic Health in Adult Rats.
Topics: Adipose Tissue, White; Animals; Body Weight; Caloric Restriction; Dietary Supplements; Eating; Energ | 2021 |
Diagnosis and body mass index effects on hippocampal volumes and neurochemistry in bipolar disorder.
Topics: Adolescent; Adult; Aspartic Acid; Bipolar Disorder; Body Mass Index; Brain; Case-Control Studies; Cr | 2017 |
Pinitol alleviates systemic inflammatory cytokines in human obesity by a mechanism involving unfolded protein response and sirtuin 1.
Topics: Adipose Tissue; Adult; Aged; Anti-Inflammatory Agents; Cytokines; Endoplasmic Reticulum Stress; Fema | 2018 |
Clinical and metabolic outcomes in pregnant women at risk for gestational diabetes mellitus supplemented with myo-inositol: a secondary analysis from 3 RCTs.
Topics: Adult; Diabetes Mellitus, Type 2; Diabetes, Gestational; Dietary Supplements; Female; Fetal Growth R | 2018 |
SGLT6 - A pharmacological target for the treatment of obesity?
Topics: Animals; Anti-Obesity Agents; Caco-2 Cells; Food Preferences; Glucose; Heat-Shock Proteins; HEK293 C | 2018 |
Eruptive xanthomas in a patient with soft-drink diabetic ketosis and apolipoprotein E4/2.
Topics: 3-Hydroxybutyric Acid; Acetoacetates; Adolescent; Apolipoprotein E2; Apolipoprotein E4; Carbonated B | 2019 |
Effects of three treatment modalities (diet, myoinositol or myoinositol associated with D-chiro-inositol) on clinical and body composition outcomes in women with polycystic ovary syndrome.
Topics: Adult; Body Composition; Diet Therapy; Female; Folic Acid; Humans; Inositol; Inositol Phosphates; Me | 2019 |
Differential insulin response to oral glucose tolerance test (OGTT) in overweight/obese polycystic ovary syndrome patients undergoing to myo-inositol (MYO), alpha lipoic acid (ALA), or combination of both.
Topics: Adult; Androstenedione; Drug Therapy, Combination; Estradiol; Female; Follicle Stimulating Hormone; | 2019 |
Efficacy of combination therapy of inositols, antioxidants and vitamins in obese and non-obese women with polycystic ovary syndrome: an observational study.
Topics: Adult; Antioxidants; Body Mass Index; Body Weight; Combined Modality Therapy; Dietary Supplements; F | 2020 |
Premature impairment of methylation pathway and cardiac metabolic dysfunction in fa/fa obese Zucker rats.
Topics: Adipose Tissue, White; Age Factors; Animals; Betaine; Disease Models, Animal; Inositol; Liver; Magne | 2013 |
The Combined therapy myo-inositol plus D-Chiro-inositol, in a physiological ratio, reduces the cardiovascular risk by improving the lipid profile in PCOS patients.
Topics: Adult; Cardiovascular Diseases; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; | 2013 |
Dyslipidemia links obesity to early cerebral neurochemical alterations.
Topics: Adult; Aspartic Acid; Blood Glucose; Blood Pressure; Body Mass Index; Brain; Brain Diseases; Cholest | 2013 |
Insulin-mimicking bioactivities of acylated inositol glycans in several mouse models of diabetes with or without obesity.
Topics: 3T3-L1 Cells; Adipocytes; Animal Feed; Animals; Blood Glucose; Diabetes Mellitus, Experimental; Dise | 2014 |
Abnormalities in myo-inositol metabolism associated with type 2 diabetes in mice fed a high-fat diet: benefits of a dietary myo-inositol supplementation.
Topics: Adipokines; Adipose Tissue, White; Animals; Diabetes Mellitus, Type 2; Diet, High-Fat; Dietary Suppl | 2015 |
Renal depletion of myo-inositol is associated with its increased degradation in animal models of metabolic disease.
Topics: Animals; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Hypertension; Inositol; Inositol O | 2015 |
The effect of combined inositol supplementation on maternal metabolic profile in pregnancies complicated by metabolic syndrome and obesity.
Topics: Animals; Biomarkers; Blood Glucose; Dietary Supplements; Disease Models, Animal; Female; Gastric Inh | 2016 |
Chronic administration of voglibose, an alpha-glucosidase inhibitor, increases active glucagon-like peptide-1 levels by increasing its secretion and decreasing dipeptidyl peptidase-4 activity in ob/ob mice.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Experimental; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidas | 2009 |
Inositol pyrophosphates inhibit Akt signaling, thereby regulating insulin sensitivity and weight gain.
Topics: Adipogenesis; Aging; Animals; Cell Culture Techniques; Diet; Diphosphates; Inositol; Inositol Phosph | 2010 |
Indirect effects of elevated body mass index on memory performance through altered cerebral metabolite concentrations.
Topics: Adult; Aspartic Acid; Biomarkers; Body Mass Index; Brain; Choline; Cognition Disorders; Creatine; Fe | 2012 |
Suppression of body weight gain preserves acute insulin response to glucose in the portal vein of spontaneously type 2 diabetic rats with visceral obesity.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Type 2; Fatty Acids, Nonesterified; Glucose; Glucose Tole | 2005 |
Metabolic effects of a novel silicate inositol complex of the nitric oxide precursor arginine in the obese insulin-resistant JCR:LA-cp rat.
Topics: Animals; Arginine; Blood Glucose; Body Weight; Eating; Female; Inositol; Insulin; Insulin Resistance | 2007 |
Signal transduction in isolated islets from the ob/ob mouse: enhanced sensitivity of protein kinase C to stimulation.
Topics: Animals; Cells, Cultured; Female; Glucose; Inositol; Inositol Phosphates; Insulin; Insulin Secretion | 1996 |
Dietary myoinositol results in lower urine glucose and in lower postprandial plasma glucose in obese insulin resistant rhesus monkeys.
Topics: Animals; Blood Glucose; Food, Fortified; Glycosuria; Inositol; Insulin; Insulin Resistance; Macaca m | 1996 |
Insulin-like effect of pinitol.
Topics: Animals; Blood Glucose; Cell Line; Chromones; Deoxyglucose; Diabetes Mellitus, Experimental; Dose-Re | 2000 |
D-chiro-inositol--its functional role in insulin action and its deficit in insulin resistance.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Type 1; Glycogen Synthase; Inositol; Insulin; Insulin Res | 2002 |
D-chiro-inositol--its functional role in insulin action and its deficit in insulin resistance.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Type 1; Glycogen Synthase; Inositol; Insulin; Insulin Res | 2002 |
D-chiro-inositol--its functional role in insulin action and its deficit in insulin resistance.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Type 1; Glycogen Synthase; Inositol; Insulin; Insulin Res | 2002 |
D-chiro-inositol--its functional role in insulin action and its deficit in insulin resistance.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Type 1; Glycogen Synthase; Inositol; Insulin; Insulin Res | 2002 |
Metabolic abnormalities of the hyperglycemic obese Zucker rat.
Topics: Animals; Fructose; Glucose; Glycosuria; Hyperglycemia; Inositol; Male; Obesity; Rats; Rats, Zucker; | 1992 |
[Risk factors of developing diabetic complications].
Topics: Animals; Diabetes Mellitus, Type 1; Diabetic Angiopathies; Diabetic Retinopathy; Female; Glycoprotei | 1991 |
Insulin stimulates inositol incorporation in hippocampus of lean but not obese Zucker rats.
Topics: Animals; Blood Glucose; Female; Hippocampus; Inositol; Inositol Phosphates; Insulin; Membrane Lipids | 1990 |
Biosynthesis of hippurate, urea and pyrimidines in the fatty liver: studies with rats fed orotic acid or a diet deficient in choline and inositol, and with genetically obese (Zucker) rats.
Topics: Ammonium Chloride; Animals; Benzoates; Choline Deficiency; Diet; Fatty Liver; Gluconeogenesis; Hippu | 1989 |